These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 23718301

  • 1. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S, Montoto S.
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [Abstract] [Full Text] [Related]

  • 2. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L.
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [Abstract] [Full Text] [Related]

  • 3. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD.
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J.
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, Porpaczy E, Weber M, Knogler T, Sillaber C, Jaeger U, Simonitsch-Klupp I, Ubl P, Müllauer L, Dolak W, Lukas J, Raderer M.
    Clin Cancer Res; 2015 Jun 01; 21(11):2506-13. PubMed ID: 25733598
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 18F-FDG PET in children with lymphomas.
    Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Hustinx R.
    Eur J Nucl Med Mol Imaging; 2005 Jan 01; 32(1):31-8. PubMed ID: 15605288
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P, Groupe de Travail SOR.
    Bull Cancer; 2003 Feb 01; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract] [Full Text] [Related]

  • 15. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.
    Q J Nucl Med Mol Imaging; 2008 Mar 01; 52(1):9-16. PubMed ID: 18235420
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T, Nihashi T, Hotta T, Nagai H.
    J Nucl Med; 2008 Jan 01; 49(1):13-21. PubMed ID: 18077527
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J, Qiao W, Wang C, Wang T, Xing Y.
    Hematology; 2007 Oct 01; 12(5):423-30. PubMed ID: 17852456
    [Abstract] [Full Text] [Related]

  • 19. Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma.
    Kluge R, Kurch L, Georgi T, Metzger M.
    Semin Nucl Med; 2017 May 01; 47(3):242-257. PubMed ID: 28417854
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.